BCM
EBS icon

BlueCrest Capital Management’s Emergent Biosolutions EBS Stock Holding History

BlueCrest Capital Management’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-5,064
Closed -$267K – 1562
2018
Q1 		$267K Buy
+5,064
New +$252K 0.01% 1129

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return

BlueCrest Capital Management's EBS Position: Q2 2018 in Review

BlueCrest Capital Management sold out of Emergent Biosolutions (EBS) in Q2 2018, closing a stake of 5,064 shares — an estimated $267K sold.

BlueCrest Capital Management first reported a position in EBS in Q1 2018 and held it in 1 quarter. The position peaked at $267K in Q1 2018. 263 funds tracked by Wall St. Rank hold EBS as of Q2 2018.

  • BlueCrest Capital Management reported no remaining Emergent Biosolutions position as of Q2 2018 after selling out during the quarter.
  • BlueCrest Capital Management sold 5,064 Emergent Biosolutions shares in Q2 2018, an estimated $267K.
  • BlueCrest Capital Management first reported a position in Emergent Biosolutions in Q1 2018 and held it in 1 quarter.
  • BlueCrest Capital Management's Emergent Biosolutions position peaked at $267K in Q1 2018.
  • 263 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2018.

Based on BlueCrest Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.